MicroRNAs are aberrantly expressed in hypertrophic heart

Do they play a pole in cardiac hypertrophy?

Yunhui Cheng, Ruirui Ji, Junming Yue, Jian Yang, Xiaojun Liu, He Chen, David B. Dean, Chunxiang Zhang

Research output: Contribution to journalArticle

412 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate gene expression. Although miRNAs are highly expressed in the heart, their roles in heart diseases are currently unclear. Using microarray analysis designed to detect the majority of mammalian miRNAs identified thus far, we demonstrated that miRNAs are aberrantly expressed in hypertrophic mouse hearts. The time course of the aberrant miRNA expression was further identified in mouse hearts at 7, 14, and 21 days after aortic banding. Nineteen of the most significantly dysregulated miRNAs were further confirmed by Northern blot and/or real-time polymerase chain reaction, in which miR-21 was striking because of its more than fourfold increase when compared with the sham surgical group. Similar aberrant expression of the most up-regulated miRNA, miR-21, was also found in cultured neonatal hypertrophic cardiomyocytes stimulated by angiotensin II or phenylephrine. Modulating miR-21 expression via antisense-mediated depletion (knockdown) had a significant negative effect on cardiomyocyte hypertrophy. The results suggest that miRNAs are involved in cardiac hypertrophy formation. miRNAs might be a new therapeutic target for cardiovascular diseases involving cardiac hypertrophy such as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders.

Original languageEnglish (US)
Pages (from-to)1831-1840
Number of pages10
JournalAmerican Journal of Pathology
Volume170
Issue number6
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Fingerprint

Cardiomegaly
MicroRNAs
Cardiac Myocytes
Endocrine System Diseases
Small Untranslated RNA
Phenylephrine
Microarray Analysis
Angiotensin II
Northern Blotting
Hypertrophy
Myocardial Ischemia
Real-Time Polymerase Chain Reaction
Heart Diseases
Cardiovascular Diseases
Hypertension
Gene Expression

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

MicroRNAs are aberrantly expressed in hypertrophic heart : Do they play a pole in cardiac hypertrophy? / Cheng, Yunhui; Ji, Ruirui; Yue, Junming; Yang, Jian; Liu, Xiaojun; Chen, He; Dean, David B.; Zhang, Chunxiang.

In: American Journal of Pathology, Vol. 170, No. 6, 01.01.2007, p. 1831-1840.

Research output: Contribution to journalArticle

Cheng, Yunhui ; Ji, Ruirui ; Yue, Junming ; Yang, Jian ; Liu, Xiaojun ; Chen, He ; Dean, David B. ; Zhang, Chunxiang. / MicroRNAs are aberrantly expressed in hypertrophic heart : Do they play a pole in cardiac hypertrophy?. In: American Journal of Pathology. 2007 ; Vol. 170, No. 6. pp. 1831-1840.
@article{998421b14352490496549f9d32785922,
title = "MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a pole in cardiac hypertrophy?",
abstract = "MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate gene expression. Although miRNAs are highly expressed in the heart, their roles in heart diseases are currently unclear. Using microarray analysis designed to detect the majority of mammalian miRNAs identified thus far, we demonstrated that miRNAs are aberrantly expressed in hypertrophic mouse hearts. The time course of the aberrant miRNA expression was further identified in mouse hearts at 7, 14, and 21 days after aortic banding. Nineteen of the most significantly dysregulated miRNAs were further confirmed by Northern blot and/or real-time polymerase chain reaction, in which miR-21 was striking because of its more than fourfold increase when compared with the sham surgical group. Similar aberrant expression of the most up-regulated miRNA, miR-21, was also found in cultured neonatal hypertrophic cardiomyocytes stimulated by angiotensin II or phenylephrine. Modulating miR-21 expression via antisense-mediated depletion (knockdown) had a significant negative effect on cardiomyocyte hypertrophy. The results suggest that miRNAs are involved in cardiac hypertrophy formation. miRNAs might be a new therapeutic target for cardiovascular diseases involving cardiac hypertrophy such as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders.",
author = "Yunhui Cheng and Ruirui Ji and Junming Yue and Jian Yang and Xiaojun Liu and He Chen and Dean, {David B.} and Chunxiang Zhang",
year = "2007",
month = "1",
day = "1",
doi = "10.2353/ajpath.2007.061170",
language = "English (US)",
volume = "170",
pages = "1831--1840",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - MicroRNAs are aberrantly expressed in hypertrophic heart

T2 - Do they play a pole in cardiac hypertrophy?

AU - Cheng, Yunhui

AU - Ji, Ruirui

AU - Yue, Junming

AU - Yang, Jian

AU - Liu, Xiaojun

AU - Chen, He

AU - Dean, David B.

AU - Zhang, Chunxiang

PY - 2007/1/1

Y1 - 2007/1/1

N2 - MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate gene expression. Although miRNAs are highly expressed in the heart, their roles in heart diseases are currently unclear. Using microarray analysis designed to detect the majority of mammalian miRNAs identified thus far, we demonstrated that miRNAs are aberrantly expressed in hypertrophic mouse hearts. The time course of the aberrant miRNA expression was further identified in mouse hearts at 7, 14, and 21 days after aortic banding. Nineteen of the most significantly dysregulated miRNAs were further confirmed by Northern blot and/or real-time polymerase chain reaction, in which miR-21 was striking because of its more than fourfold increase when compared with the sham surgical group. Similar aberrant expression of the most up-regulated miRNA, miR-21, was also found in cultured neonatal hypertrophic cardiomyocytes stimulated by angiotensin II or phenylephrine. Modulating miR-21 expression via antisense-mediated depletion (knockdown) had a significant negative effect on cardiomyocyte hypertrophy. The results suggest that miRNAs are involved in cardiac hypertrophy formation. miRNAs might be a new therapeutic target for cardiovascular diseases involving cardiac hypertrophy such as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders.

AB - MicroRNAs (miRNAs) are a recently discovered class of endogenous, small, noncoding RNAs that regulate gene expression. Although miRNAs are highly expressed in the heart, their roles in heart diseases are currently unclear. Using microarray analysis designed to detect the majority of mammalian miRNAs identified thus far, we demonstrated that miRNAs are aberrantly expressed in hypertrophic mouse hearts. The time course of the aberrant miRNA expression was further identified in mouse hearts at 7, 14, and 21 days after aortic banding. Nineteen of the most significantly dysregulated miRNAs were further confirmed by Northern blot and/or real-time polymerase chain reaction, in which miR-21 was striking because of its more than fourfold increase when compared with the sham surgical group. Similar aberrant expression of the most up-regulated miRNA, miR-21, was also found in cultured neonatal hypertrophic cardiomyocytes stimulated by angiotensin II or phenylephrine. Modulating miR-21 expression via antisense-mediated depletion (knockdown) had a significant negative effect on cardiomyocyte hypertrophy. The results suggest that miRNAs are involved in cardiac hypertrophy formation. miRNAs might be a new therapeutic target for cardiovascular diseases involving cardiac hypertrophy such as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders.

UR - http://www.scopus.com/inward/record.url?scp=34447318648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447318648&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2007.061170

DO - 10.2353/ajpath.2007.061170

M3 - Article

VL - 170

SP - 1831

EP - 1840

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -